Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — CF&B Frankfurt Midcap Event 2023
16 slides from Svas Biosana's conference presentation, October 2023
Slide 1: CF&B Frankfurt Midcap Event
CF&B Frankfurt Midcap Event October 2023 Strictly Private and Confidential
Slide 2: Shareholders’ Structure & Key People
Shareholders’ Structure & Key People Shareholders (1) Key People Free Float Umberto 31,12% Perillo 43,86% SVAS Biosana S.p.A. 4,09% Umberto Perillo Andrea Efficace Chief Executive Officer Mark Medical CEO & Group CFO Agrinvest S.r.l. 0,93% Danila Antonia Perillo Mr. Perillo is the General Director a
Slide 3: Group Overview
Group Overview SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting Svas Biosana «At a Glance» both as a manufacturer and as a distributor. Key Financial Highlights The Group was founded in Southern Italy in 1972
Slide 4: Group Overview: Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices ▪ Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division ❑ Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical ❑ Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 5: Group Overview: Business Snapshot
Group Overview Legend Production & Sale Business Snapshot Distribution & Sale Company Activity Production Distribution Business €17,4m €4,6m €8,8m Mark €17,8m €7,0m Farmex Medical Svas Bormia Line(1) 31% 8% 16% Medical 32% 13% Incontinence Products Custom Packs & Specialist Disposables Advanced Medi
Slide 6: Production – Main products
Production – Main products Farmex Medical Adult Incontinence Aids Custom Pack Standard Dressings Cotton Wool Advanced Dressings Surgical Suction Infusion and Systems Drainage Devices Svas Biosana Investor Presentation October 2023 6
Slide 7: Distribution – Main products
Distribution – Main products Specialties Cardiac Surgery Orthopedics and Arthroscopy Drug Transfer Devices for Peritoneal Dyalisis Cardiopulmonary TAVI Orthopedic Arthroscopy Implants Devices Anesthesia Products Implants and Equipment Radiology & Imaging Cardiology Laparoscopic Advanced Hemostatic C
Slide 8: Group Overview: H1 2023 Sales Breakdown
Group Overview H1 2023 Sales Breakdown By Activity By Geography By Customer Type Production Private 40% Customers Foreign ~ 30% Countries H1 2023 FY 2022 Italy Sales1 H1 2023 FY 2022 45% Sales1 55% Distribution 60% Public Customers ~ 70% First-class Suppliers National Public Hospitals Public Purchas
Slide 9: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 10: Financial Data
Financial Data Key Financial Highlights Millions of Euro EBITDA Net Revenues Millions of Euro 2018A 2019A 2020A 2021A 2022A H1 2022 H1 2023 Millions of Euro 97,2 14,0 € 100,0 € 11,9 81,1 12,0 € 10,6 Net Revenue 69,1 73,6 76,0 81,1 97,2 43,8 54,9 73,6 76,0 9,2 9,6 20,0% 80,0 € 69,1 10,0 € 8,3 YoY Δ 6
Slide 11: Annex: Group Structure
Annex Group Structure Absolute majority of shares owned by Umberto Perillo Board of Directors Umberto Danila Antonia Svas Biosana Free Float Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Filippo Maraniello Perillo Perillo S.p.A. Chairman 43,86% 6,35% 4,09% 0,93% 8,19% 5,46% 31,12% Umberto Peri
Slide 12: Annex: H1 Consolidated Income Statement
Annex H1 Consolidated Income Statement 30/06/2022 % 30/06/2023 % Delta % Revenues from sales and services 43.843.886 100% 54.939.038 100% 11.095.152 25% External costs (33.165.592) 76% (43.144.031) 79% 9.978.439 30% Added Value 10.678.294 24% 11.795.007 21% 1.116.713 10% Cost of labor (5.822.602) 13
Slide 13: Annex: H1 Consolidated Balance Sheet
Annex H1 Consolidated Balance Sheet 31/12/2022 30/06/2023 Delta Net intangible fixed assets 11.023.670 11.350.040 326.370 Net tangible fixed assets 26.209.159 25.804.005 (405.154) Equity investments and other financial fixed assets 229.980 110.179 (119.801) Fixed capital 37.462.809 37.264.224 (198.5
Slide 14: Annex: Consolidated Income Statement
Annex Consolidated Income Statement 31/12/2021 % 31/12/2022 % Delta % Revenues from sales and services 81.085.102 100,0% 97.226.932 100,0% 16.141.830 19,9% External costs 60.383.563 74,5% 74.943.464 77,1% 14.559.901 24,1% Added Value 20.701.539 25,5% 22.283.468 22,9% 1.581.929 7,6% Cost of labor 11.
Slide 15: Annex: Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31/12/2021 31/12/2022 Delta Net intangible fixed assets 10.749.503 11.023.670 274.167 Net tangible fixed assets 25.639.396 26.209.159 569.763 Equity investments and other financial fixed assets 159.786 229.980 70.194 Fixed capital 36.548.685 37.462.809 914.124 Invent
Slide 16: Legal Disclaimer
Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared by Svas Biosana S.p.A. (the “Company”) solely for information and d